JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M303304200 on August 9, 2003

J. Biol. Chem., Vol. 278, Issue 43, 42346-42351, October 24, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/43/42346    most recent
M303304200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zannini, L.
Right arrow Articles by Delia, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zannini, L.
Right arrow Articles by Delia, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Karyopherin-{alpha}2 Protein Interacts with Chk2 and Contributes to Its Nuclear Import*

Laura Zannini{ddagger}, Daniele Lecis, Sofia Lisanti, Roberta Benetti{ddagger}§, Giacomo Buscemi, Claudio Schneider§, and Domenico Delia

From the Department of Experimental Oncology, Istituto Nazionale Tumori, 20133 Milan and §Laboratorio Nazionale Consorzio Interuniversitario per le Biotecnologie c/o AREA Science Park, Padriciano, I-34012 Trieste, Italy

Received for publication, March 31, 2003 , and in revised form, July 30, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Chk2 is a nuclear protein kinase involved in the DNA damage-induced ataxia telangiectasia mutated-dependent checkpoint arrest at multiple cell cycle phases. Searching for Chk2-binding proteins by a yeast two-hybrid system, we identified a strong interaction with karyopherin-{alpha}2 (KPNA-2), a gene product involved in active nuclear import of proteins bearing a nuclear localization signal (NLS). This finding was confirmed by glutathione S-transferase pull-down and co-immunoprecipitation assays. Of the three predicted Chk2 NLSs, located at amino acids 179-182 (NLS-1), 240-256 (NLS-2), and 515-522 (NLS-3), only the latter mediated the interaction with KPNA-2 in the yeast two-hybrid system, and in particular with its C terminus. Unlike mutations in NLS-1 or NLS-2, which left the nuclear localization of Chk2 unaffected, mutations in NLS-3 caused a cytoplasmic relocalization, indicating that the NLS-3 motif acts indeed as NLS for Chk2 in vivo. Finally, co-transfection experiments with green fluorescent protein (GFP)-Chk2 and wild type or mutant KPNA-2 confirmed the role of KPNA-2 in nuclear import of Chk2.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
To prevent genomic instability and cancer, DNA lesions arising from external agents or internal metabolism activate multiple checkpoint pathways that coordinate DNA repair and cell cycle progression. The checkpoint protein Chk2, the mammalian homologue of Saccharomyces cerevisiae Rad53 and Schizosaccharomyces pombe Cds1 (1), is a nuclear serine kinase bearing a serine/threonine-(SQ/TQ)-rich region (aa1 19-69) with several potential phosphorylation sites, a phosphoprotein-interacting FHA domain (aa 115-175), and a catalytic domain (aa 226-486) (2). In response to genotoxic agents, including {gamma}-radiation (IR), Chk2 is phosphorylated on Thr68 by ataxia telangiectasia mutated, the protein mutated in ataxia telangiectasia disease (3-5). Additional steps of phosphorylation, dependent on the expression of a functional Nbs1/Mre11/Rad50 complex (6), promote the full activation of Chk2 and phosphorylation of its substrates (e.g. p53, Cdc25A, Cdc25C, Brca1) involved in checkpoint arrest at G1, S, and G2/M transitions (7-11). Most recently, additional molecules have been found to interact with Chk2. Among these, the adaptor proteins 53BP1 (12, 13) and NFBD1/Mdc1 (14-16) seem to facilitate Chk2 activation, the kinases Plk-3 and Plk-1 phosphorylate Chk2 (17-19), and PML behaves as a substrate for Chk2 and modulates apoptosis (20).

To find out Chk2-interacting proteins, we have undertaken yeast two-hybrid screens using either full-length or deletion forms of Chk2 as baits and a human cDNA library from HeLa cells. Here we report that Chk2 interacts with karyopherin-{alpha}2 (KPNA-2), a family member of molecules involved in the nuclear translocation of target proteins that carry a nuclear localization signal (NLS) motif characterized by short stretches of basic amino acids (21, 22). NLSs can be monopartite if containing a single stretch of basic amino acids, bipartite if containing two stretches of basic amino acids separated by a spacer region. The nuclear translocation of target proteins by KPNA-2 requires the binding to karyopherin-{beta}, which allows passage of the complex through the nuclear pore (23, 24). Once in the nucleus, the binding of Ran-GTP to karyopherin-{beta} causes the dissociation with KPNA-2, thereby allowing it to release its cargo and to finally recycle to the cytoplasm via interaction with export proteins (25). Here we show that the C terminus of KPNA-2 binds the NLS-3 sequence of Chk2 and that this interaction has a role in the nuclear localization of Chk2 in cells.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Cells and Transfections—The lymphoblastoid cell line LCL-N from a normal donor was cultured in RPMI 1640 medium (BioWhittaker, Walkersville, MD) supplemented with 15% heat-inactivated fetal calf serum, penicillin (100 units/ml), and streptomycin (100 µg/ml), whereas the U2OS osteosarcoma cell line was maintained in Dulbecco's modified Eagle's medium with 10% serum. Cells were transfected by the calcium phosphate method. Irradiations were performed in an IBL437CO instrument equipped with a 137Ce source emitting a dose of 8 grays/min.

Yeast Two-hybrid Screening—The screening in yeast was performed as described (26). Briefly, Chk2 c-DNA deleted of aa 76-213 (obtained by digestion of full-length Chk2 c-DNA with AocI) was cloned in the EcoRI-SalI sites of pLexA vector in-frame with the Lex A DNA binding domain and used as a bait to transform the EGY48 yeast strain. A selected clone was then transformed with a HeLa c-DNA library cloned in the pJG4-5 vector in-frame with the B42 transactivation domain. About 2 x 106 clones were obtained and tested for their capacity to grow in a medium without leucine and by the X-gal filter method. Plasmid DNA was then extracted from positive clones, and the c-DNA inserts were amplified by PCR and analyzed by sequencing. To map the regions of interaction between Chk2 and KPNA-2, deletion mutants for the two proteins were prepared by PCR and cloned in the pLexA and in pJG4-5 vector. The constructs were then used to transform the EGY48 strain and tested for the interaction using a medium containing X-gal or without leucine.

GST Pull-down Assays—The GST-Chk2 recombinant protein was purified from bacteria transformed with the full-length Chk2 cDNA cloned in the EcoRI-NotI sites of pGEX-4T-1 vector. LCL-N cells were lysed in ice-cold ELB buffer (150 mM NaCl, 50 mM Hepes, pH 7.5, 5 mM EDTA, 0.1% Nonidet P-40), and 1 mg of cell extracts were incubated for 3 h at 4 °C with 10 µg of GST-Chk2 or GST together with glutathione-Sepharose. The beads were extensively washed in lysis buffer, size-fractionated by SDS-PAGE, and immunoblotted for KPNA-2 using a specific monoclonal antibody (Clone 2, Transduction Laboratories).

Co-immunoprecipitations—LCL-N, unirradiated or irradiated with 10 grays of IR, and U2OS cells transiently transfected with pCDNA3-HA-Chk2 and pCDNA3-FLAG-KPNA-2 were lysed in ELB buffer. After preclearing with protein A/G-coupled Sepharose beads, lysates were immunoprecipitated with an anti-Chk2 polyclonal antibody (27) or with the anti-FLAG M2 monoclonal antibody (Sigma) and extensively washed. Immunoprecipitates were analyzed by Western blot with monoclonal antibodies anti-KPNA-2 (Clone 2, Transduction Laboratories) and anti-Chk2 (Clone 44D4-21, generated in our laboratory).

Site-directed Mutagenesis—Mutations in the full-length Chk2 cDNA cloned in the EcoRI-NotI sites of pCDNA3-FLAG vector were introduced by the Gene Editor kit (Promega). To mutagenize the lysine and arginine residues to alanine, the oligonucleotide primers used were 5'-AGCTGGCTTTCGAGGCGGCAACATGTAAGAAAG-3' (Chk2 bp 704-737) and 5'-AGATCATCAGCAAAGCGGCGTTTGCTATTGGTT-3' (Chk2 bp 746-779) for the bipartite NLS (NLS-2) and 5'-CTTCTACTAGTCGAGCGGCGCCCCGTGAAGGGG-3' (Chk2 bp 1544-1577) for the NLS-3. The sequences were always verified by automatic DNA sequencing.

Immunofluorescence Analysis—U2OS cell lines were transiently transfected with pCDNA3-carrying wild type or mutant forms of FLAG-tagged Chk2. After 48 h, the cells were cytocentrifuged on glass slides, fixed with 3.7% paraformaldehyde, permeabilized in 0.2% Triton X-100, and immunostained with the anti-FLAG-M2 monoclonal antibody (Sigma). Binding of primary antibodies was revealed with a fluorescein isothiocyanate-labeled F(ab')2 anti-mouse antibody (Jackson Laboratories). Nuclei were stained with 4',6 diamidino-2-phenylindole, and coverslips were mounted with an anti-fade solution. Slides were analyzed using a Zeiss Axioskop (Oberkochen, Germany) fluorescence microscope and digital imaging.

GFP-Chk2/FLAG-KPNA-2 Co-expression—To establish the role in vivo of Chk2/KPNA-2 interaction, Chk2 cDNA was cloned in the EcoRI-SalI sites of pEGFP-C vector, whereas full-length or deletion mutants of KPNA-2 cDNAs were cloned in the EcoRI-XhoI sites of pcDNA3-FLAG vector. FLAG-KPNA-2 and GFP-Chk2 constructs were co-transfected in U2OS cells at a ratio of 6:1, respectively, and 48 h later, the subcellular localization of GST-Chk2 was analyzed by fluorescence microscopy.

In Vitro Chk2 Kinase Assays—Kinase reactions were performed using a catalytically active GST-Chk2 recombinant protein (2 µg) incubated for 30 min at 30 °C with 1 µg of either GST-KPNA-2 or GST-Cdc25C substrate (the latter used as positive control) in 30 µl of kinase buffer (20 mM Tris-HCl, 75 mM KCl, 5 mM MgCl2, 0.5 mM EDTA, 2 mM dithiothreitol, 50 µM ATP, and 15 µCi of [{gamma}-32P]ATP). The reaction products were separated by SDS-PAGE and autoradiographed. The gels were then stained with Coomassie Blue to visualize the amount of loaded substrate per lane.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Yeast Two-hybrid Screenings for Chk2 Interactors—The yeast two-hybrid system was employed to search for Chk2 interactors. The bait consisted of Chk2 deleted of aa 76-213 rather than full-length Chk2 (Fig. 1, a and b), because in preliminary tests, the latter partially inhibited the growth and consequently the transformation efficiency of yeast (data not shown). Approximately two million colonies were screened by the X-gal filter method and for their capacity to grow without leucine. Of 45 sequenced positive clones, 33 encoded the full length or fragments of the karyopherin-{alpha}2 (KPNA-2) protein, the shortest of which represent aa 285-529. KPNA-2 (21, 22) is a nuclear transporter of proteins bearing an NLS, structurally characterized by an N terminus importin-{beta} binding (IBB) domain necessary for nuclear translocation, eight armadillo repeats involved in the binding and recognition of NLSs, and a C-terminal acidic domain (Fig. 1c).



View larger version (8K):
[in this window]
[in a new window]
 
FIG. 1.
Domain structure of human Chk2 and KPNA-2. In a, the diagram depicts the TQ/SQ-rich region and the FHA and kinase domains of Chk2 protein. b, the Chk2 bait deleted of aa 76-213 used in the yeast two-hybrid screening. c, schematic representation of the IBB domain, the armadillo repeats, and the acidic domain of KPNA-2 protein.

 

Chk2 Interacts with KPNA-2 Both in Vitro and in Vivo—The physical interaction between Chk2 and KPNA-2 was initially examined in pull-down assays in which extracts from normal lymphoblastoid cells (LCL-N) were incubated with Sepharose-bound recombinant GST-Chk2. Under these conditions, the endogenous KPNA-2 bound GST-Chk2 but not GST (Fig. 2a), thus confirming the interaction seen in yeast. To verify this interaction in vivo, we determined whether Chk2 immunoprecipitates with KPNA-2. The results (Fig. 2b, lane 3) showed that Chk2 from LCL-N cells co-precipitated with KPNA-2, and the specificity of this finding was demonstrated by the absence of a KPNA-2 signal when immunoprecipitating with a control antibody (Fig. 2b, lane 2). As Chk2 is involved in the response to DNA damage (1, 2), we tested the effect of IR on the interaction between Chk2 and KPNA-2. In cells treated with 10 grays of IR and harvested 3 h later, Chk2 co-precipitated KPNA-2 to the same extent as in untreated cells (Fig. 2b, lane 7). As Chk2 protein could not be detected in KPNA-2 immunoprecipitates (possibly because the epitope recognized by the monoclonal anti-KPNA-2 antibody sits in the region binding to Chk2, see below), we transiently co-transfected U2OS cell lines with FLAG-KPNA-2 and HA-Chk2 constructs and analyzed Chk2 in KPNA-2 immunoprecipitates obtained with anti-FLAG antibody. Under these conditions, we were able to find HA-Chk2 protein associated with KPNA-2 (Fig. 2c, lane 4). Altogether, these results demonstrate an interaction between Chk2 and KPNA-2 in human cells.



View larger version (39K):
[in this window]
[in a new window]
 
FIG. 2.
Physical association between Chk2 and KPNA-2. a, pull-down assays with GST-Chk2 (lane 2) or GST (lane 3); lane 1, the total cell lysate. Note the interaction of KPNA-2 with GST-Chk2 only. The blot was normalized by Coomassie Blue staining. W.B., Western blot. b, Western blot analysis of Chk2 immunocomplexes from LCL-N cells. Lanes 1 and 5, lysates from unirradiated or irradiated cells, respectively; lanes 2 and 6, negative controls; lanes 3 and 7, Chk2 immunoprecipitates from unirradiated and irradiated cells; lanes 4 and 8, immunodepleted lysates. It can be seen that the interaction between Chk2 and KPNA-2 is not influenced by the radiation treatment. c, Western blot analysis of FLAG-KPNA-2 immunoprecipitates from U2OS cell lines. Lanes 1 and 2, total lysates from untransfected and transfected cells, respectively; lane 3, negative control; lane 4, immunoprecipitation with the FLAG antibody; lane 5, immunodepleted lysate.

 

Identification of the Sites of Interaction between Chk2 and KPNA-2—To map the region of interaction between Chk2 and KPNA-2, the full-length and deleted versions of these proteins were tested in the yeast two-hybrid system. Initially, three Chk2 deletions were made, carrying the TQ/SQ-rich region plus the FHA domain (Chk21-209), the kinase domain only (Chk2210-543), or the C terminus (Chk2450-543). Besides full-length Chk2, Chk2210-543 and Chk2450-543, but not Chk21-209, interacted with full-length KPNA-2 (Fig. 3a), indicating that the KPNA-2 binding site is located at aa 450-543 of Chk2. Because the shortest KPNA-2 sequence found in the initial two-hybrid screening encoded the C-terminal 244 amino acids, it was clear that this sequence mediated the interaction with Chk2. Thus, to narrow down the region of interaction, mutants deleted of the acidic domain (KPNA-21-460) or acidic domain plus the two terminal armadillo repeats (KPNA-21-369) were tested in yeast against full-length Chk2. As neither KPNA-21-460 nor KPNA-21-369 interacted with Chk2 (Fig. 3b), it can be concluded that aa 461-529 of KPNA-2 are required for binding to Chk2. The expression of KPNA-21-460 and KPNA-21-369 proteins in yeast was demonstrated by Western blot with an anti-LexA antibody. Of note, these mutant proteins were, in contrast to full-length KPNA-2, unreactive with the anti-KPNA-2 antibody (Fig. 3c), suggesting that aa 461-520 contain the anti-KPNA-2 binding epitope.



View larger version (20K):
[in this window]
[in a new window]
 
FIG. 3.
Identification of KPNA-2/Chk2 interacting sequences. As shown in a, deletion mutants of Chk2 were fused to LexA DNA binding domain and used to map by yeast two-hybrid-interacting regions with full-length KPNA-2. b, deletion mutants of KPNA-2 used to map the binding region with full-length Chk2 in yeast. The clones were streaked on medium containing X-gal or without leucine to detect the two reporter gene expression. Positive interactions (+) or no interactions (-) in the yeast two-hybrid system are indicated. c, Western blot analysis of yeast extracts expressing full-length or deletion mutants of KPNA-2. Lanes 1, full-length KPNA-2; lanes 2, KPNA-21-369; lanes 3, KPNA-21-460. The left panel shows the reactivity with the {alpha}-LexA antibody, whereas the right panel shows the reactivity of the same blot with the anti-KPNA-2 monoclonal antibody.

 

Identification of Chk2 NLS—As KPNA-2 mediates the nuclear import of proteins carrying the NLS sequence (22), we determined the possible involvement of such an NLS of Chk2 in the interaction with KPNA-2. A PSORT II computer program analysis of Chk2 sequence identified three putative NLSs, a monopartite NLS-1 (KRRP, aa 179-182), a bipartite NLS-2 (RKTCKKVAIKIISKRKF, aa 240-256), and a monopartite NLS-3 (PSTSRKRPR, aa 515-522) (Fig. 4a). To study the function of these putative NLSs, the localization of various Chk2 NLS mutants expressed in transiently transfected U2OS cells was assessed by immunofluorescence. Like full-length FLAG-Chk2, FLAG-Chk2 deleted of aa 76-213 (and therefore of NLS-1) was exclusively expressed in the nucleus, thus suggesting that NLS-1 is dispensable for Chk2 nuclear localization. By contrast, a cytoplasmic localization became evident (Fig. 4b) when the lysine 520 and arginine 521 of NLS-3 were substituted with alanine (Table I). These changes are thought to destroy the putative consensus sequence. Mutations in NLS-2 motif had no effect on Chk2 nuclear localization (Table I and Fig. 4b). In accordance with these findings, KPNA-2 failed to interact in yeast with Chk2 mutated in NLS-3 (Fig. 4c). These results underscore the role of NLS-3 in the interaction with KPNA-2 and nuclear localization of Chk2.



View larger version (38K):
[in this window]
[in a new window]
 
FIG. 4.
Immunofluorescence staining of Chk2 mutants in the putative NLSs. a, the positions along the Chk2 c-DNA sequence of the three putative NLSs, a monopartite at aa 179-182, a bipartite at aa 240-256, and another monopartite at aa 515-522, predicted by the PSORT II computer program. b, U2OS cells were transiently transfected with FLAG-Chk2 constructs and immunostained with anti-FLAG antibody. Note the nuclear localization of Chk2 deleted of aa 76-213 or mutated in the NLS-2 and the cytoplasmic localization of Chk2 mutated in the NLS-3. W.T., wild type; DAPI, 4',6 diamidino-2-phenylindole. c, yeast two-hybrid results showing the disruption of the interaction between KPNA-2 and Chk2 mutated in the NLS-3 sequence.

 

View this table:
[in this window]
[in a new window]
 
TABLE I
Chk2 mutants in the NLSs

The table shows wild type and mutated NLS-2 and NLS-3 used to identify the functional Chk2 NLS.

 

Function of the Chk2/KPNA-2 Interaction in Vivo—To determine the in vivo function of Chk2/KPNA-2 association, we examined the effect of ectopically expressed KPNA-2 on the nuclear translocation of Chk2. U2OS cells were transiently co-transfected with plasmids encoding GFP-Chk2 and wild type or mutant KPNA-2 and examined by fluorescence microscopy. Of the fluorescent cells detected in co-transfections with GFP-Chk2 and an empty vector, 51% showed a nuclear labeling, whereas the remaining, in addition, showed a cytoplasmic labeling whose intensity was in some cases much weaker than the nuclear fluorescence. After co-transfection with wild type KPNA-2, the number of cells with nuclear GFP-Chk2 (Fig. 5) rose to 66%, whereas after co-transfection with KPNA-2 deleted of either the Chk2-interacting region (KPNA-21-460) or the IBB domain (KPNA-270-529, unable to translocate to the nucleus), the number dropped to 41%, indicating a role for KPNA-2 in the nuclear translocation of Chk2 kinase.



View larger version (17K):
[in this window]
[in a new window]
 
FIG. 5.
KPNA-2 overexpression and Chk2 subcellular localization. The intracellular distribution of GFP-Chk2 was examined by fluorescence microscopy after transient co-transfection of U2OS cells with wild type or deleted forms of FLAG-KPNA-2. The mean number (±S.D., shown as error bars) of cells with a nuclear fluorescence only (N; dark shaded columns), cells with similar nuclear and cytoplasmic fluorescence intensity (N=C; light shaded columns), and cells with much dimer cytoplasmic than nuclear fluorescence (N>C; open columns) are shown. Note that the nuclear localization of GFP-Chk2 increases when overexpressing wild type KPNA-2 and decreases when overexpressing mutant KPNA-2.

 

Since certain kinases modulate their nuclear import by direct phosphorylation of KPNA-2 (28), we assessed whether KPNA-2 is a target substrate for Chk2 kinase. For this purpose, in vitro kinase assays were performed using catalytically active recombinant GST-Chk2 and full-length GST-KPNA-2 as a substrate. However, whereas GST-Chk2 phosphorylated, as expected, Cdc25C, it failed to phosphorylate KPNA-2 (Fig. 6a), thus excluding a phosphorylative event in the interaction of these proteins. This finding is concordant with the lack of a Chk2 consensus substrate motif within KPNA-2 (as determined by Scansite analysis) and with the normal nuclear localization of ectopically expressed Chk2 kinase-dead (Fig. 6b).



View larger version (19K):
[in this window]
[in a new window]
 
FIG. 6.
Recombinant Chk2 does not phosphorylate KPNA-2. Enzymatically active recombinant GST-Chk2 was tested for its capacity to phosphorylate KPNA-2 or GST-Cdc25c (the latter used as positive control). No KPNA-2 phosphorylation was detected (a). Normalization with Coomassie Blue staining is shown. b, normal nuclear localization of FLAG-Chk2-KD (kinase-dead) transiently expressed in U2OS cells.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Two-hybrid screenings in yeast have enabled us to identify a new physical and functional interaction between Chk2 kinase and KPNA-2, a family member of proteins involved in the active transport from the cytoplasm to the nucleus of cargo proteins containing an NLS (21, 22). Two types of NLS motifs exist; one, exemplified by the SV40 large T antigen PKKKRKV, contains a short stretch of basic amino acids (monopartite), and the other, first reported in nucleoplasmin (KRPAATKKAGQAKKKKLDK), contains two clusters of basic amino acids separated by a spacer region of 10-12 amino acids (bipartite). To cross the nuclear membrane and deliver its NLS-tagged cargo, KPNA-2 has to bind karyopherin-{beta} (23, 24). In the nucleus, these complex components, including the cargo, are released, allowing the recycling of karyopherins to the cytoplasm (25).

We confirmed the interaction seen in yeast between Chk2 and KPNA-2 also in pull-down assays between recombinant GST-Chk2 and endogenous KPNA-2 from total cell lysates. We have additionally demonstrated that Chk2 immunocomplexes from unirradiated or irradiated cells, the latter expressing hyperphosphorylated Chk2 (1, 2), contain KPNA-2. The detection by mass spectrometry of KPNA-2 in FLAG-Chk2 immunocomplexes extracted from cells2 lends further support to these results. Although we were unable to co-precipitate Chk2 with anti-KPNA-2 antibodies, reasonably because the epitope that it recognizes maps within the region of interaction with Chk2 (as we have shown in Western blots of KPNA-2 deletion mutants expressed in yeast) and may thus be unavailable when bound to Chk2, we could nevertheless demonstrate Chk2 in FLAG-KPNA-2 complexes immunoprecipitated with an anti-FLAG antibody from cells ectopically expressing FLAG-KPNA-2 and HA-Chk2.

Having confirmed the interaction between these two molecules, we next determined whether this was mediated by the NLSs. As the PSORT analysis of Chk2 cDNA sequence scored three NLS motifs localized at aa 179-182 (NLS-1; monopartite), aa 240-256 (NLS-2; bipartite), aa 515-522 (NLS-3; monopartite), we examined in the two-hybrid system various missense and/or deletion mutants of Chk2 and KPNA-2 and found that only the C-terminal aa 450-543 of Chk2, which comprises NLS-3, associates with KPNA-2.

To determine the functional role in vivo of the three putative NLSs, the intracellular distribution of FLAG-tagged Chk2 constructs transiently transfected in U2OS cells was analyzed by immunofluorescence. We have shown that mutations in NLS-3, but not in NLS-1 or NLS-2, cause a cytoplasmic redistribution of Chk2. This finding, together with the fact that NLS-3 mutations disrupt the interaction with KPNA-2 in yeast (see above), underscores the importance of NLS-3 for the binding to KPNA-2 and nuclear translocation of Chk2.

KPNA-2 contains an IBB, eight armadillo repeats typically involved in recognition and binding to NLSs, and a C-terminal acidic domain (22). We have established that the C-terminal aa 461-529 of KPNA-2 are indispensable for binding to Chk2. This result is in apparent contrast with the finding that the armadillo repeats mediate the binding to NLS (22), but concordant with others showing that proteins such as RAG-1, BSAP, Stat1, and the export protein CAS interact with the C-terminal region of the karyopherin family members (29-32). It is speculated that the use of C-terminal region for interactions allows karyopherins to bind more than one molecule at the time, giving rise to a scaffold for protein complexes (31).

To establish the role played by KPNA-2 in the nuclear transport of Chk2, the subcellular localization of GFP-Chk2 co-expressed with wild type or mutant versions of KPNA-2 was analyzed by fluorescence microscopy. We have shown that only 51% of GFP-Chk2 cells have a nuclear localization, the remaining exhibiting both nuclear and cytoplasmic fluorescence of various intensities. It is worth noting that this cytoplasmic localization was not observed in cells expressing FLAG-Chk2, suggesting that the conformation of GFP-Chk2 might impair its nuclear transport. Interestingly, when co-expressed with wild type KPNA-2, the fraction of cells with nuclear GFP-Chk2 fluorescence rose to 66%, whereas when co-expressed with KPNA-2 mutated in the Chk2 binding site or in the IBB domain (thus unable to reach the nucleus), this number fell to 41%. Altogether, these results indicate that overexpression of wild type KPNA-2 enhances the nuclear localization of GFP-Chk2, whereas the mutant forms of KPNA-2 do not significantly modify the subcellular distribution of Chk2. These data may not be unexpected since there is no evidence indicating that the KPNA-2 mutants could act as dominant negative. Moreover, given the redundancy of the nuclear import/export pathways, other members of the karyopherin isoforms (33) could possibly complement KPNA-2 defects. This hypothesis is supported by experiments showing that the selective inhibition of KPNA-2 protein expression by small interfering RNA treatment only induces a 2-fold increase in cells with cytoplasmic GFP-Chk2, rather than an abrogation of nuclear GFP-Chk2 import,3 indicating that other karyopherin family members could partake in Chk2 nuclear import, like certain ribosomal and core histone proteins whose nuclear transport is mediated by at least five different importins (34). It should be noticed, however, that additional two-hybrid screenings in yeast with various Chk2 baits and different cDNA libraries have never revealed interactions with the karyopherin family other than KPNA-2.

As the Itk kinase stimulates its nuclear import through the phosphorylation of KPNA-2 (28), we tried to establish whether Chk2 operates in a similar way. However, we were unable to demonstrate, at least in vitro, any phosphorylation of GST-KPNA-2 by Chk2, indicating that the nuclear transport of Chk2 by KPNA-2 is independent of its enzymatic activity, which actually concurs with the appropriate nuclear localization of the kinase-inactive form of Chk2.

In conclusion, we have shown that Chk2 kinase carries a functional NLS located at aa 515-522 indispensable for KPNA-2 binding and that this interaction contributes to Chk2 nuclear translocation. As proteins of the nuclear import machinery, including KPNA-2, appear to have a role in other physiological processes, e.g. mitotic spindle formation, RNA export, and chromatin structure (35-37), we cannot exclude that Chk2-KPNA-2 association solely regulates Chk2 nuclear import.


    FOOTNOTES
 
* This work was financially supported by the Italian Telethon Grant GP0205Y-01, the Italian Association for Cancer Research (AIRC), the National Research Council (CNR) and the Italian Ministry of Health (Ricerca Finalizzata). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} Recipients of fellowships from the Italian Foundation for Cancer Research. Back

To whom correspondence should be addressed: Dept. of Experimental Oncology, Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milano, Italy. Tel.: 39-02-23902641; Fax: 39-02-23902764; E-mail: domenico.delia{at}istitutotumori.mi.it.

1 The abbreviations used are: aa, amino acids; FHA, forkhead-associated; GST, glutathione S-transferase; GFP, green fluorescent protein; NLS, nuclear localization signal; HA, hemagglutinin; KPNA-2, karyopherin-{alpha}2; IBB, importin-{beta} binding; X-gal, 5-bromo-4-chloro-3-indolyl-{beta}-D-galactopyranoside. Back

2 L. Zannini, personal communication. Back

3 L. Zannini, unpublished observation. Back


    ACKNOWLEDGMENTS
 
We thank Dr. M. Nakanishi for kindly providing the polyclonal antibody against Chk2 and M. T. Radice for help with microbiological techniques and site-directed mutagenesis.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Matsuoka, S., Huang, M., and Elledge, S. J. (1998) Science 282, 1893-1897[Abstract/Free Full Text]
  2. Bartek, J., Falck, J., and Lukas, J. (2001) Nat. Rev. Mol. Cell. Biol. 2, 877-886[CrossRef][Medline] [Order article via Infotrieve]
  3. Ahn, J. Y., Schwarz, J. K., Piwnica-Worms, H., and Canman, C. E. (2000) Cancer Res. 60, 5934-5936[Abstract/Free Full Text]
  4. Melchionna, R., Chen, X. B., Blasina, A., and McGowan, C. H. (2000) Nat. Cell Biol. 2, 762-765[CrossRef][Medline] [Order article via Infotrieve]
  5. Matsuoka, S., Rotman, G., Ogawa, A., Shiloh, Y., Tamai, K., and Elledge, S. J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10389-10394[Abstract/Free Full Text]
  6. Buscemi, G., Savio, C., Zannini, L., Miccichè, F., Masnada, D., Nakanishi, M., Tauchi, H., Komatsu, K., Mizutani, S., Khanna, K., Chen, P., Concannon, P., Chessa, L., and Delia, D. (2001) Mol. Cell. Biol. 21, 5214-5222[Abstract/Free Full Text]
  7. Hirao, A., Kong, Y. Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu, D., Elledge, S. J., and Mak, T. W. (2000) Science 287, 1824-1827[Abstract/Free Full Text]
  8. Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y., and Prives, C. (2000) Genes Dev. 14, 289-300[Abstract/Free Full Text]
  9. Chehab, N. H., Malikzay, A., Appel, M., and Halazonetis, T. D. (2000) Genes Dev. 14, 278-288[Abstract/Free Full Text]
  10. Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J., and Lukas, J. (2001) Nature 410, 842-847[CrossRef][Medline] [Order article via Infotrieve]
  11. Chaturvedi, P., Eng, W. K., Zhu, Y., Mattern, M. R., Mishra, R., Hurle, M. R., Zhang, X., Annan, R. S., Lu, Q., Faucette, L. F., Scott, G. F., Li, X., Carr, S. A., Johnson, R. K., Winkler, J. D., and Zhou, B. B. (1999) Oncogene 18, 4047-4054[CrossRef][Medline] [Order article via Infotrieve]
  12. Wang, B., Matsuoka, S., Carpenter, P. B., and Elledge, S. J. (2002) Science 298, 1435-1438[Abstract/Free Full Text]
  13. DiTullio, R. A. Jr., Mochan, T. A., Venere, M., Bartkova, J., Sehested, M., Bartek, J., and Halazonetis, T. D. (2002) Nat. Cell Biol. 4, 998-1002[CrossRef][Medline] [Order article via Infotrieve]
  14. Peng, A., and Chen, P. L. (2003) J. Biol. Chem. 278, 8873-8876[Abstract/Free Full Text]
  15. Shang, Y. L., Bodero, A. J., and Chen, P. L. (2003) J. Biol. Chem. 278, 6323-6329[Abstract/Free Full Text]
  16. Lou, Z., Minter-Dykhouse, K., Wu, X., and Chen, J. (2003) Nature 421, 957-961[CrossRef][Medline] [Order article via Infotrieve]
  17. Xie, S., Wu, H., Wang, Q., Kunicki, J., Thomas, R. O., Hollingsworth, R. E., Cogswell, J., and Dai, W. (2002) Cell Cycle 1, 424-429[Medline] [Order article via Infotrieve]
  18. Bahassi el, M., Conn, C. W., Myer, D. L., Hennigan, R. F., McGowan, C. H., Sanchez, Y., and Stambrook, P. J. (2002) Oncogene 21, 6633-6640[CrossRef][Medline] [Order article via Infotrieve]
  19. Tsvetkov, L. M., Xu, X., Li, J., and Stern, D. F. (2003) J. Biol. Chem. 278, 8468-8475[Abstract/Free Full Text]
  20. Yang, S., Kuo, C., Bisi, J. E., and Kim, M. K. (2002) Nat. Cell Biol. 4, 865-870[CrossRef][Medline] [Order article via Infotrieve]
  21. Nakielny, S., and Dreyfuss, G. (1999) Cell 99, 677-690[CrossRef][Medline] [Order article via Infotrieve]
  22. Chook, Y. M., and Blobel, G. (2001) Curr. Opin. Struct. Biol. 11, 703-715[CrossRef][Medline] [Order article via Infotrieve]
  23. Gorlich, D., Henklein, P., Laskey, R. A., and Hartmann, E. (1996) EMBO J. 15, 1810-1817[Medline] [Order article via Infotrieve]
  24. Weis, K., Ryder, J., and Lamond, A. I. (1996) EMBO J. 15, 1818-1825[Medline] [Order article via Infotrieve]
  25. Moroianu, J., Blobel, G., and Radu, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7059-7062[Abstract/Free Full Text]
  26. Benetti, R., Del Sal, G., Monte, M., Paroni, G., Brancolini, C., and Schneider, C. (2001) EMBO J. 20, 2702-2714[CrossRef][Medline] [Order article via Infotrieve]
  27. Tominaga, K., Morisaki, H., Kaneko, Y., Fujimoto, A., Tanaka, T., Ohtsubo, M., Hirai, M., Okayama, H., Ikeda, K., and Nakanishi, M. (1999) J. Biol. Chem. 274, 1463-1467
  28. Perez-Villar, J. J., O'Day, K., Hewgill, D. H., and Nadler, S. G. (2001) Int. Immunol. 13, 1265-1274[Abstract/Free Full Text]
  29. Cuomo, C. A., Kirch, S. A., Gyuris, J., Brent, R., and Oettinger, M. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6156-6160[Abstract/Free Full Text]
  30. Kovac, C. R., Emelyanov, A., Singh, M., Ashouian, N., and Birshtein, B. K. (2000) J. Biol. Chem. 275, 16752-16757[Abstract/Free Full Text]
  31. Sekimoto, T., Imamoto, N., Nakajima, K., Hirano, T., and Yoneda, Y. (1997) EMBO J. 16, 7067-7077[CrossRef][Medline] [Order article via Infotrieve]
  32. Herold, A., Truant, R., Wiegand, H., and Cullen, B. R. (1998) J. Cell Biol. 143, 309-318[Abstract/Free Full Text]
  33. Köhler, M., Speck, C., Christiansen, M., Bischoff, F. R., Prehn, S., Haller, H., Görlich, D., and Hartmann, E. (1999) Mol. Cell. Biol. 19, 7782-7791[Abstract/Free Full Text]
  34. Weis, K. (2002) Curr. Opin. Cell Biol. 14, 328-335[CrossRef][Medline] [Order article via Infotrieve]
  35. Gruss, O. J., Carazo-Salas, R. E., Schatz, C. A., Guarguaglini, G., Kast, J., Wilm, M., Le Bot, N., Vernos, I., Karsenti, E., and Mattaj, I. W. (2001) Cell 104, 83-93[CrossRef][Medline] [Order article via Infotrieve]
  36. Cullen, B. R. (2003) J. Cell Sci. 116, 587-597[Abstract/Free Full Text]
  37. Galy, V., Olivo-Marin, J. C., Schertan, H., Doye, V., Rascalou, N., and Nehrbass, U. (2000) Nature 403, 108-112[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
L. Carlessi, G. Buscemi, G. Larson, Z. Hong, J. Z. Wu, and D. Delia
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2
Mol. Cancer Ther., March 1, 2007; 6(3): 935 - 944.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Y. Pereg, S. Lam, A. Teunisse, S. Biton, E. Meulmeester, L. Mittelman, G. Buscemi, K. Okamoto, Y. Taya, Y. Shiloh, et al.
Differential Roles of ATM- and Chk2-Mediated Phosphorylations of Hdmx in Response to DNA Damage.
Mol. Cell. Biol., September 1, 2006; 26(18): 6819 - 6831.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Yoda, X. Z. Xu, N. Onishi, K. Toyoshima, H. Fujimoto, N. Kato, I. Oishi, T. Kondo, and Y. Minami
Intrinsic Kinase Activity and SQ/TQ Domain of Chk2 Kinase as Well as N-terminal Domain of Wip1 Phosphatase Are Required for Regulation of Chk2 by Wip1
J. Biol. Chem., August 25, 2006; 281(34): 24847 - 24862.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Gaspar and T. Shenk
Human cytomegalovirus inhibits a DNA damage response by mislocalizing checkpoint proteins
PNAS, February 21, 2006; 103(8): 2821 - 2826.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-F. Tseng, C.-Y. Chang, K.-J. Wu, and S.-C. Teng
Importin KPNA2 Is Required for Proper Nuclear Localization and Multiple Functions of NBS1
J. Biol. Chem., November 25, 2005; 280(47): 39594 - 39600.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
D. Delia, M. Piane, G. Buscemi, C. Savio, S. Palmeri, P. Lulli, L. Carlessi, E. Fontanella, and L. Chessa
MRE11 mutations and impaired ATM-dependent responses in an Italian family with ataxia-telangiectasia-like disorder
Hum. Mol. Genet., September 15, 2004; 13(18): 2155 - 2163.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/43/42346    most recent
M303304200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zannini, L.
Right arrow Articles by Delia, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zannini, L.
Right arrow Articles by Delia, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.